Patents by Inventor Jordi Mata-Fink

Jordi Mata-Fink has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE
    Publication number: 20210154272
    Abstract: Described herein are methods for treating a subject having or at risk of developing cancer administering a neuromodulating agent.
    Type: Application
    Filed: October 5, 2020
    Publication date: May 27, 2021
    Inventors: Erica WEINSTEIN, Jordi MATA-FINK, Avak KAHVEJIAN, Noubar B. AFEYAN, Laura Kristina JEANBART, Alexandra LANTERMANN, Jonathan Barry HUROV, Manuel Andreas FANKHAUSER, Chengyi J. SHU, Eric Franklin ZHU
  • Methods and compositions for treating cancer using SERCA pump inhibitors
    Patent number: 11013717
    Abstract: The present invention provides methods for treating cancer using sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump inhibitors, such as SERCA pump inhibitory antibodies, among others. The invention also features compositions containing SERCA pump inhibitors, methods of diagnosing patients with SERCA pump-associated cancer, and methods of predicting the response of cancer in a subject to treatment with SERCA pump inhibitors.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: May 25, 2021
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Jonathan Barry Hurov, Chengyi Jenny Shu, Eric Franklin Zhu, Katherine Mary Molloy
  • CRISPR-RELATED METHODS AND COMPOSITIONS
    Publication number: 20210040506
    Abstract: Methods and compositions useful in targeting a payload to or editing a target nucleic acid are disclosed herein.
    Type: Application
    Filed: July 24, 2020
    Publication date: February 11, 2021
    Applicant: Editas Medicine, Inc.
    Inventors: Alexandra GLUCKSMANN, Debrah PALESTRANT, Louis Anthony TARTAGLIA, Jordi MATA-FINK, Agnieszka Dorota CZECHOWICZ
  • Methods and compositions for immunomodulation
    Patent number: 10869898
    Abstract: Provided are cells containing exogenous antigen and uses thereof.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: December 22, 2020
    Assignee: Rubius Therapeutics, Inc.
    Inventors: Jordi Mata-Fink, John Round, Noubar B. Afeyan, Avak Kahvejian
  • METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY OR AUTOIMMUNE DISEASES OR CONDITIONS USING CHRNA6 ACTIVATORS
    Publication number: 20200360364
    Abstract: The present invention provides methods for treating inflammatory or autoimmune diseases or conditions using activators tin of nicotinic acetylcholine receptors (nAChRs) containing a cholinergic receptor nicotinic alpha 6 subunit (nAChR?S), such as activating antibodies that bind to a nAChR containing a nAChP?6 subunit and small molecule agonists of nAChRs containing a nAChR?S subunit. The invention also features compositions containing ?6*nAChR activators, methods of diagnosing patients with an ?6*nAChR-associated inflammatory or autoimmune disease or condition, and methods of predicting the response of an inflammatory or autoimmune disease or condition in a subject to treatment with ?6*nAChR activators.
    Type: Application
    Filed: January 31, 2019
    Publication date: November 19, 2020
    Inventors: Avak KAHVEJIAN, Jordi MATA-FINK, Jonathan Barry HUROV, Chengyi Jenny SHU, Manuel Andreas FANKHAUSER, Julian Alexander STANLEY
  • COMPOSITIONS AND METHODS RELATED TO CELL SYSTEMS FOR PENETRATING SOLID TUMORS
    Publication number: 20200345845
    Abstract: The present disclosure provides, e.g., compositions and method for treating cancers, e.g., solid tumors. In embodiments, the compositions comprise an erythroid cell expressing an exogenous polypeptide, e.g., a polypeptide that promotes penetration of the erythroid cell into the solid tumor.
    Type: Application
    Filed: April 9, 2020
    Publication date: November 5, 2020
    Inventors: Avak Kahvejian, Robert J. Deans, Jordi Mata-Fink, Sivan Elloul, Nathan Dowden
  • CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS
    Publication number: 20200308604
    Abstract: Disclosed herein are methods and compositions useful in targeting a payload to, or editing a target nucleic acid, where a governing gRNA molecule is used to target, optionally inactivate, a Cas9 molecule or a Cas9 molecule/gRNA complex.
    Type: Application
    Filed: March 31, 2020
    Publication date: October 1, 2020
    Applicants: EDITAS MEDICINE, INC., THE BROAD INSTITUTE INC., THE UNIVERSITY OF IOWA RESEARCH FOUNDATION, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Feng ZHANG, Deborah PALESTRANT, Beverly DAVIDSON, Jordi MATA-FINK, Edgardo RODRIGUEZ, Alexis BORISY
  • Compositions and methods related to multimodal therapeutic cancer indications
    Patent number: 10716811
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: July 21, 2020
    Assignee: Rubius Therapeutics Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • Methods for treating cancer using GRM8 inhibitors
    Patent number: 10683352
    Abstract: The present invention provides methods for treating cancer using mGluR8 inhibitors, such as mGluR8 inhibitory antibodies and small molecules. The invention also features compositions containing mGluR8 inhibitors, methods of diagnosing patients with mGluR8-associated cancer, and methods of predicting the response of cancer in a subject to treatment with mGluR8 inhibitors.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: June 16, 2020
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Jonathan Barry Hurov, Chengyi Jenny Shu, George Huck Neubauer, Julian Alexander Stanley
  • COMPOSITIONS AND METHODS RELATED TO MULTIMODAL THERAPEUTIC CELL SYSTEMS FOR INFECTIOUS DISEASE
    Publication number: 20200172868
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating an infectious disease. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having an infectious disease.
    Type: Application
    Filed: July 19, 2017
    Publication date: June 4, 2020
    Inventors: Tom Wickham, Tiffany F. Chen, Nathan Dowden, Robert Finberg, Robert J. Deans, John Round, Avak Kahvejian, Jordi Mata-Fink, Noubar B. Afeyan
  • COMPOSITIONS AND METHODS RELATED TO MULTIMODAL THERAPEUTIC CELL SYSTEMS FOR CARDIOMETABOLIC DISEASE
    Publication number: 20200172867
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating cardiovascular diseases and metabolic disorders. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cardiovascular disease or metabolic disorder.
    Type: Application
    Filed: July 19, 2017
    Publication date: June 4, 2020
    Inventors: Tom Wickham, Tiffany F. Chen, Torben Straight Nissen, Nathan Dowden, Robert J. Deans, John Round, Avak Kahvejian, Jordi Mata-Fink, Noubar B. Afeyan
  • CRISPR-related methods and compositions with governing gRNAs
    Patent number: 10640788
    Abstract: Disclosed herein are methods and compositions useful in targeting a payload to, or editing a target nucleic acid, where a governing gRNA molecule is used to target, optionally inactivate, a Cas9 molecule or a Cas9 molecule/gRNA complex.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: May 5, 2020
    Assignees: Editas Medicine, Inc., The Broad Institute Inc., Massachusetts Institute of Technology, University of Iowa Reseach Foundation
    Inventors: Feng Zhang, Deborah Palestrant, Beverly Davidson, Jordi Mata-Fink, Edgardo Rodriguez, Alexis Borisy
  • COMPOSITIONS AND METHODS RELATED TO ENGINEERED ERYTHROID CELLS COMPRISING IL-15
    Publication number: 20200129556
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Application
    Filed: January 8, 2020
    Publication date: April 30, 2020
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • Compositions and methods related to engineered erythroid cells comprising IL-15
    Patent number: 10568910
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: February 25, 2020
    Assignee: RUBIUS THERAPEUTICS, INC.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • Erythroid cells comprising phenylalanine ammonia lyase
    Patent number: 10557119
    Abstract: Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: February 11, 2020
    Assignee: RUBIUS THERAPEUTICS, INC.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, John Round, David Arthur Berry, Noubar B. Afeyan
  • METHODS RELATED TO ENGINEERED ERYTHOID CELLS COMPRISING 4-1BBL
    Publication number: 20200016209
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Application
    Filed: September 18, 2019
    Publication date: January 16, 2020
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • ERYTHROID CELLS COMPRISING PHENYLALANINE HYDROXYLASE
    Publication number: 20200002674
    Abstract: Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
    Type: Application
    Filed: September 16, 2019
    Publication date: January 2, 2020
    Inventors: Avak Kahvejian, Jordi Mata-Fink, John Round, David Arthur Berry, Noubar B. Afeyan
  • Methods related to engineered erythoid cells comprising 4-1BBL
    Patent number: 10517897
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: December 31, 2019
    Assignee: RUBIUS THERAPEUTICS, INC.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • METHODS AND COMPOSITIONS FOR IMMUNOMODULATION
    Publication number: 20190388473
    Abstract: Provided are cells containing exogenous antigen and uses thereof.
    Type: Application
    Filed: August 30, 2019
    Publication date: December 26, 2019
    Inventors: Jordi Mata-Fink, John Round, Noubar B. Afeyan, Avak Kahvejian
  • PLATELETS COMPRISING EXOGENOUS POLYPEPTIDES AND USES THEREOF
    Publication number: 20190376034
    Abstract: Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
    Type: Application
    Filed: August 23, 2019
    Publication date: December 12, 2019
    Inventors: Avak Kahvejian, Jordi Mata-Fink, John Round, David Arthur Berry, Noubar B. Afeyan